Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/9435
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCroke, Simonen
dc.contributor.authorBuist, Anneen
dc.contributor.authorHackett, L Peteren
dc.contributor.authorIlett, Kenneth Fen
dc.contributor.authorNorman, Trevor Ren
dc.contributor.authorBurrows, Graham Den
dc.date.accessioned2015-05-15T22:31:51Z
dc.date.available2015-05-15T22:31:51Z
dc.date.issued2002-09-01en
dc.identifier.citationThe International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (cinp); 5(3): 243-7en
dc.identifier.govdoc12366877en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/9435en
dc.description.abstractNewer antipsychotic drugs offer significant clinical advantages for the treatment of psychosis. In particular for the treatment of postpartum disorders newer agents may be suited due to their favourable side-effect profiles. Of concern is the passage of the drugs into breast milk and what potential risks this poses for an infant who is breastfed. The excretion of olanzapine into the breast milk of five lactating women with postpartum psychosis was examined in this study. Nine pairs of plasma and breast-milk samples were collected and the concentration of olanzapine determined by high-performance liquid chromatography. Single-point milk-to-plasma ratios were calculated and ranged from 0.2 to 0.84 with a mean of 0.46. The median relative infant dose was 1.6% (range 0-2.5%) of the weight-adjusted maternal dose. During the study period, there were no apparent ill effects on the infant as a consequence of exposure to these doses of olanzapine. As with other antipsychotic drugs this study demonstrates that olanzapine passes into breast milk. The long-term effects of exposure in infants exposed to olanzapine requires further investigation.en
dc.language.isoenen
dc.subject.otherAdulten
dc.subject.otherAntipsychotic Agents.blood.pharmacokinetics.therapeutic useen
dc.subject.otherBenzodiazepinesen
dc.subject.otherDepression, Postpartum.drug therapy.metabolism.psychologyen
dc.subject.otherFemaleen
dc.subject.otherHumansen
dc.subject.otherInfanten
dc.subject.otherInfant, Newbornen
dc.subject.otherMilk, Human.metabolismen
dc.subject.otherPirenzepine.analogs & derivatives.blood.pharmacokinetics.therapeutic useen
dc.subject.otherPsychiatric Status Rating Scalesen
dc.titleOlanzapine excretion in human breast milk: estimation of infant exposure.en
dc.typeJournal Articleen
dc.identifier.journaltitleThe international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)en
dc.identifier.affiliationsimon.croke@armc.org.uaen
dc.identifier.affiliationDepartment of Psychiatry, University of Melbourne, Austin & Repatriation Medical Centre, Heidelberg, Victoria, Australiaen
dc.identifier.doidoi:10.1017/S1461145702003012en
dc.description.pages243-7en
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/12366877en
Appears in Collections:Journal articles

Files in This Item:
File Description SizeFormat 
12366877.pdf189.78 kBAdobe PDFThumbnail
View/Open


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.